Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is a Healthcare company (Biotechnology) with a market capitalization of $6.1B. The Maz Rating grades it against the other companies in its sector.
Arrowhead Pharmaceuticals, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $42.99, Arrowhead Pharmaceuticals, Inc. trades at 13.9x sales and 124.5x book value. Over the last twelve months it generated about $438M of revenue and a net loss of $700M. It runs a gross margin of 99.6%, an operating margin of -156.9% and a net margin of -160.6%. It shows return on equity of -170.6%, return on invested capital of -47.6% and a free cash flow yield of -4.5%. On the balance sheet: a debt-to-equity ratio of 19.88 and a current ratio of 4.14. Over the past 52 weeks the share price ranged from $37.06 to $95.49, with a beta of 1.37.
Arrowhead Pharmaceuticals, Inc. does not currently pay a dividend.
22 Wall Street analyst ratings cover the stock: 16 Buy and 6 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.